Literature DB >> 26888777

Sympathomodulatory Effects of Antihypertensive Drug Treatment.

Guido Grassi1.   

Abstract

BACKGROUND: An activation of sympathetic neural influences to the heart and peripheral circulation has been shown to represent a hallmark of the essential hypertensive state, adrenergic neural factors participating together with other variables at the development and progression of the high blood pressure state as well as of the hypertension-related target organ damage. This represents the rationale for employing in hypertension treatment drugs which combine the blood pressure-lowering properties with the modulatory effects on the sympathetic neural function. METHODS AND
RESULTS: Several studies published during the past 40 years have investigated the impact of antihypertensive drugs on the sympathetic target as assessed by indirect and direct approaches. In the present paper, the effects of different monotherapies or combination drug treatment used in hypertension to lower elevated blood pressure values on various adrenergic markers will be examined. This will be followed by a discussion of the (i) hemodynamic and nonhemodynamic consequences of employing antihypertensive drugs with sympathomodulatory or sympathoexcitatory properties and (ii) mechanisms potentially responsible for the adrenergic responses to a given antihypertensive drug. The final part of this review will address the questions still open related to the impact of antihypertensive drug treatment on sympathetic function. Two questions in particular will be examined, i.e., whether antihypertensive drugs with sympathomodulatory properties may be capable to fully restore a "normal" adrenergic drive and how far sympathetic activity should be reduced in hypertensive patients.
CONCLUSION: Future investigations aimed at answering these questions will be needed in order to improve cardiovascular protection in treated hypertensive patients. © American Journal of Hypertension, Ltd 2016. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antihypertensive drugs; blood pressure; cardiovascular risk; hypertension; sympathetic nervous system; sympathomodulation.

Mesh:

Substances:

Year:  2016        PMID: 26888777     DOI: 10.1093/ajh/hpw012

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

Review 1.  Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.

Authors:  Raven Voora; Alan L Hinderliter
Journal:  Curr Hypertens Rep       Date:  2018-09-07       Impact factor: 5.369

Review 2.  The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Clin Auton Res       Date:  2018-11-09       Impact factor: 4.435

Review 3.  Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance.

Authors:  Leon J DeLalio; Alan F Sved; Sean D Stocker
Journal:  Can J Cardiol       Date:  2020-03-06       Impact factor: 5.223

4.  Prolonged Baroreflex Activation Abolishes Salt-Induced Hypertension After Reductions in Kidney Mass.

Authors:  Drew A Hildebrandt; Eric D Irwin; Thomas E Lohmeier
Journal:  Hypertension       Date:  2016-10-24       Impact factor: 10.190

Review 5.  The renin-angiotensin system and cardiovascular autonomic control in aging.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Peptides       Date:  2021-12-29       Impact factor: 3.750

6.  Assessment of parasympathetic cardiovascular activity in primary open-angle glaucoma.

Authors:  Oluwaseun O Awe; Oluwadare Ogundare; Bernice O Adegbehingbe
Journal:  Int Ophthalmol       Date:  2021-11-05       Impact factor: 2.031

Review 7.  Antihypertensive Drugs and Risk of Bone Fractures.

Authors:  Maria Velliou; Elias Sanidas; Aliki Zografou; Dimitrios Papadopoulos; Nikolaos Dalianis; John Barbetseas
Journal:  Drugs Aging       Date:  2022-06-27       Impact factor: 4.271

8.  Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study.

Authors:  Yun-Dai Chen; Xin-Chun Yang; Vinh Nguyen Pham; Shi-An Huang; Guo-Sheng Fu; Xiao-Ping Chen; Binh Quang Truong; Yu Yang; Shao-Wen Liu; Tian-Rong Ma; Dong-Soo Kim; Tae-Hoon Kim
Journal:  Chin Med J (Engl)       Date:  2020-05-20       Impact factor: 2.628

9.  Ganglionic Long-Term Potentiation in Prehypertensive and Hypertensive Stages of Spontaneously Hypertensive Rats Depends on GABA Modulation.

Authors:  Luis A Martínez; Fredy Cifuentes; Miguel A Morales
Journal:  Neural Plast       Date:  2019-10-13       Impact factor: 3.599

10.  Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection-A Proof-of-Concept Study.

Authors:  Neil A Hoye; Luke C Wilson; Gerard T Wilkins; David L Jardine; Tracey L Putt; Ari Samaranayaka; John B W Schollum; Robert J Walker
Journal:  Kidney Int Rep       Date:  2017-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.